Andromeda Biotech is focused on the development of an innovative treatment for type 1 diabetes. The Company's lead product, DiaPep277® is a unique peptide which was invented at the Weizmann Institute of Science and is fully licensed to Andromeda by the Yeda Research & Development Company.
DiaPep277® is a peptide that modulates the immune system to prevent the destruction of insulin producing cells in the pancreas. Consequently, the treatment may have several medical benefits including prevention of disease deterioration, improved glycemic control, reduction of daily insulin dose requirements, and delay or reduction of diabetic complications.
Currently, DiaPep277® is in phase III clinical studies. The first phase III study, DIA-AID 1 has been completed and met study endpoints. Treatment with DiaPep277® significantly preserved beta-cell function as determined by levels of C-peptide. Also, a higher proportion of treated patients were better metabolically controlled compared to patients on placebo and experienced fewer hypoglycemic events. Andromeda is conducting a second confirmatory Phase III study, DIA-AID 2 to obtain marketing approval in the USA and Europe. This study is being conducted at more than 120 medical centers worldwide. Patient recruitment in the DIA-AID 2 trial has been completed and the study is expected to be completed at the end of 2014.
To date, there is no therapy that can prevent the destruction of insulin secreting beta cells. DiaPep277® is designed to treat type 1 diabetes patients with residual insulin secreting cells. Potential target populations include newly diagnosed adult patients, type 1 diabetic children, people with high risk type 1 diabetes, type 1 diabetes patients with slow progressing disease, and type 2 diabetes patients with auto-antibodies.
Andromeda Biotech was founded in 2007 by Clal Biotechnology Industries (CBI).